Published randomized controlled trials of drug therapy for dementia often lack complete data on harm

Journal of Clinical Epidemiology

Volumn 61, Issue 11, 2008, Pages 1152-1160

  Lee, P E ^a   Fischer, H D ^b   Rochon, P A ^b,c,d,e   Gill, S S ^b,f   Herrmann, N ^d   Bell, C M ^b,d,e   Sykora, K ^b   Anderson, G M ^b,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

Adverse events; Alzheimer's disease; Atypical antipsychotics; Cholinesterase inhibitors; Dementia; Randomized controlled trials

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; GALANTAMINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TACRINE; ZIPRASIDONE;

ABSENCE OF SIDE EFFECTS; ADVERSE OUTCOME; ARTICLE; CLINICAL TRIAL; DEMENTIA; DRUG FATALITY; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MEDICAL LITERATURE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

AGED; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 54849184800     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2007.09.012     Document Type: Article

References (58)

1. Smith C.M. Origin and uses of primum non nocere-above all, do no harm!. J Clin Pharmacol 45 (2005) 371-377
2. Ioannidis J.P., and Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285 (2001) 437-443
3. Ioannidis J.P., Evans S.J., Gotzsche P.C., O'Neill R.T., Altman D.G., Schulz K., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141 (2004) 781-788
4. Rogers S.L., and Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7 6 (1996) 293-303
5. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., and Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60 (1999) 107-115
6. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L., Eriksson S., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 946-955
7. Mamdani M., Rapoport M., Shulman K.I., Herrmann N., and Rochon P. Mental health-related drug utilization among older adults. Am J Geriatr Psychiatry 13 (2005) 892-900
8. Bronskill S.E., Anderson G.M., Sykora K., Wodchis W.P., Gill S., Shulman K.I., et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 52 (2004) 749-755
9. Johnson & Johnson Pharmaceutical Research & Development Synopsis. GAL-INT-11. Accessed March 14, 2007. Available at. http://www.clinicalstudyresults.org/documents/company-study_96_1.pdf
10. Johnson & Johnson Pharmaceutical Research & Development Synopsis. GAL-INT-18. Accessed March 14, 2007. Available at. http://www.clinicalstudyresults.org/documents/company-study_96_2.pdf
11. Health Canada. Public advisory-Health Canada endorsed important safety information on Reminyl (galantamine). Accessed March 14, 2007. Available at (2005). http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/2005/reminy l_pa-ap_e.html
12. United States Food and Drug Administration. Reminyl (galantamine hydrobromide) prescribing information update re: patients with MCI. Accessed March 14, 2007. Available at. http://www.fda.gov/medwatch/safety/2005/reminylDDLmarch.pdf
13. Eisai Co. LCCD. Eisai reports results from latest donepezil study in vascular dementia. Accessed March 14, 2007. Available at. http://www.eisai.co.jp/enews/enews200609pdf.pdf
14. Health Canada. Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Accessed March 14, 2007. Available at. http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2005/2005_63_e.html
15. United States FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Accessed March 14, 2007. Available at. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
16. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
17. Arrieta J.L., and Artalejo F.R. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing 27 (1998) 161-179
18. Peng D., Xu X., and Hou Q. The safety and efficacy of aricept in patients with Alzheimer disease. Chin J Neurol 35 (2002) 19-21
19. Holmes C., Wilkinson D., Dean C., Vethanayagam S., Olivieri S., Langley A., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. [see comment]. Neurology 63 (2004) 214-219
20. Seltzer B., Zolnouni P., Nunez M., Goldman R., Kumar D., Ieni J., et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 61 (2004) 1852-1856
21. Courtney C., Farrell D., Gray R., Hills R., Lynch L., Sellwood E., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. [see comment]. Lancet 363 9427 (2004) 2105-2115
22. Black S., Roman G.C., Geldmacher D.S., Salloway S., Hecker J., Burns A., et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. [see comment]. Stroke 34 (2003) 2323-2330
23. Wilkinson D., Doody R., Helme R., Taubman K., Mintzer J., Kertesz A., et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61 (2003) 479-486
24. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E., et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57 (2001) 613-620
25. Tariot P.N., Cummings J.L., Katz I.R., Mintzer J., Perdomo C.A., Schwam E.M., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49 (2001) 1590-1599
26. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
27. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488
28. Greenberg S.M., Tennis M.K., Brown L.B., Gomez-Isla T., Hayden D.L., Schoenfeld D.A., et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 57 (2000) 94-99
29. Homma A., Takeda M., Imai Y., Udaka F., Hasegawa K., Kameyama M., et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 11 6 (2000) 299-313
30. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Moller H.J., et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 10 3 (1999) 237-244
31. Rogers S.L., Doody R.S., Mohs R.C., and Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158 (1998) 1021-1031
32. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., and Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50 (1998) 136-145
33. Karaman Y., Erdogan F., Koseoglu E., Turan T., and Ersoy A.O. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 19 (2005) 51-56
34. Rosler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal-Bianco P., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318 7184 (1999) 633-638
35. Forette F., Anand R., and Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 6 (1999) 423-429
36. Agid Y., Dubois B., Anand R., and Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp 59 (1998) 837-845
37. Corey-Bloom J., Anand R., and Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1 (1998) 55-65
38. Sramek J.J., Anand R., Wardle T.S., Irwin P., Hartman R.D., and Cutler N.R. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 58 (1996) 1201-1207
39. Rockwood K., Mintzer J., Truyen L., Wessel T., and Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol, Neurosurg Psychiatry 71 (2001) 589-595
40. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., and Damaraju C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359 9314 (2002) 1283-1290
41. Wilkinson D., and Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 16 (2001) 852-857
42. Wilcock G.K., Lilienfeld S., and Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321 7274 (2000) 1445-1449
43. Raskind M.A., Peskind E.R., Wessel T., and Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54 (2000) 2261-2268
44. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., and Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54 (2000) 2269-2276
45. Brodaty H., Ames D., Snowdon J., Woodward M., Kirwan J., Clarnette R., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64 2 (2003) 134-143
46. Street J.S., Clark W.S., Gannon K.S., Cummings J.L., Bymaster F.P., Tamura R.N., et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 57 (2000) 968-976
47. De Deyn P.P., Carrasco M.M., Deberdt W., Jeandel C., Hay D.P., Feldman P.D., et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 19 (2004) 115-126
48. Ballard C., Margallo-Lana M., Juszczak E., Douglas S., Swann A., Thomas A., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330 7496 (2005) 874
49. Edwards I.R., and Biriell C. Harmonisation in pharmacovigilance. Drug Saf 10 2 (1994) 93-102
50. Health Canada. Guidance for clinical trial sponsors. Clinical trial applications. Assessed March 14, 2007. Available at. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/e2d_step2_etape2_e.pdf
51. United States Food and Drug Administration. Title 21-food and drugs chapter I-Food and Drug Administration Department of Health and Human Services, subchapter D-drugs for human use. 21CFR310.305. Accessed March 14, 2007. Available at. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr =310.305
52. United States Food and Drug Administration. Title 21-food and drugs chapter I-Food and Drug Administration Department of Health and Human Services, subchapter D-drugs for human use. 21CFR314.80. Accessed March 14, 2007. Available at. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr =314.80
53. Lanctot K.L., Herrmann N., Yau K.K., Khan L.R., Liu B.A., LouLou M.M., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 169 (2003) 557-564
54. Lee P.E., Gill S.S., Freedman M., Bronskill S.E., Hillmer M.P., and Rochon P.A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329 7457 (2004) 75
55. Gill S.S., Bronskill S.E., Normand S.-L.T., Bronskill S.E., Hillmer M.P., and Rochon P.A. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146 (2007) 775-786
56. Wright J.M., Puil L., and Bassett C.L. Analysis of serious adverse events. Lipid-lowering therapy revisited. Can Fam Physician 48 (2002) 486-499
57. Miller D.B., and Humphries K.H. A new way to evaluate randomized controlled trials? New approach does more harm than good. B C Med J 47 (2005) 241-244
58. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608